Comparison Evaluation of Bone Mineral Density in Patients with Ankylosing Spondylitis Before Treatment and One Year After Treatment with Alendronate
Mohsen Soroush 1, Mohammad Mirtalebi 1 and Arman Ahmadzade 2*1Rheumatology Section, Department of Internal Medicine, AJA University of Medical Sciences, Tehran, Iran.
2Rheumatology Ward , Loghman Hakim Hospital , Shahid Beheshti University of Medical Sciences (SBMU) , Tehran , Iran.
*Corresponding Author E-mail : arman319@yahoo.com
Abstract: Ankylosing spondylitis (AS) is an inflammatory disease with an unknown cause, which primarily affects the axial skeleton. It usually appears during the second or third decade and its prevalence among men is almost three times that of women. Osteoporosis is known as a common finding in AS. Bone cytokines produced in the peripheral and axial joints in chronic inflammatory disease is responsible for systemic and local osteopenic activity. Considering the prevalence and importance of osteoporosis in patients with AS and the high costs of treatment and its dangerous and serious side effects such as fractures in patients with AS, it is necessary to evaluate the efficacy of drug agents in the patients. The purpose of this study is to evaluate the effectiveness of alendronate in patients with AS and comparison of them with standard treatment group. Total patients studied were 57. Of these, 8 cases were females and 49 cases were male. Of the 57 patients, 28 patients received the standard treatment of AS and 29 patients received Alendronate in addition to standard therapy. The average t-score and t-score mean difference of lumbar spine before and after the treatment in one-year period were calculated in both standard treatment receiving group and the group receiving standard treatment plus Alendronate. In addition to the lumbar spine, the average t-score and t-score mean difference of femoral neck were calculated for both groups. The densitometry of two groups showed that the T-score of patients in both groups were recovered after treatment compared to before therapy and the rate was more remarkable in the group treated with Alendronate. Oral bisphosphonate can be a proper substitute for the treatment of osteoporosis in this spectrum of patients.
Keywords: ankylosing spondylitis; osteoporosis; Alendronate Back to TOC